ScholarIQanswers from OpenAlex & ORCID
Masahiro Fukuoka
ResearcherPublications, citations & collaboration network
Masahiro Fukuoka is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Masahiro Fukuoka have?
ScholarIQindexed works
Masahiro Fukuoka has 374 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Masahiro Fukuoka have?
ScholarIQcitation count
Masahiro Fukuoka has 34,316 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Masahiro Fukuoka?
ScholarIQh-index
Masahiro Fukuoka has an h-index of 63 in OpenAlex.
What is the i10-index of Masahiro Fukuoka?
ScholarIQi10-index
Masahiro Fukuoka has an i10-index of 178 in OpenAlex.
What is the OpenAlex record for Masahiro Fukuoka?
ScholarIQopenalex
The OpenAlex for Masahiro Fukuoka is on the source record.
What are the most-cited papers on Masahiro Fukuoka?
ScholarIQmost cited works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo, Emma Duffield, Yuri Rukazenkov, Georgina Speake, Haiyi Jiang, Alison Armour, Ka‐Fai To, James Chih‐Hsin Yang, Tony Mok
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Takashi Seto, Terufumi Kato, Makoto Nishio, Kōichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko Nakagawa, Seisuke Nagase, Isamu Okamoto, Takeharu Yamanaka, Kosei Tajima, Ryosuke Harada, Masahiro Fukuoka, Nobuyuki Yamamoto, Nobuyuki Yamamoto
Interstitial Lung Disease in Japanese Patients with Lung Cancer
Shoji Kudoh, Harubumi Kato, Yutaka Nishiwaki, Masahiro Fukuoka, Kouichiro Nakata, Yukito Ichinose, Masahiro Tsuboi, Soichiro Yokota, Kazuhiko Nakagawa, Moritaka Suga, Haiyi Jiang, Y. Itoh, Alison Armour, Claire Watkins, Tim Higenbottam, Fredrik Nyberg
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
Riichiroh Maruyama, Yutaka Nishiwaki, Tomohide Tamura, Nobuyuki Yamamoto, Masahiro Tsuboi, Kazuhiko Nakagawa, Tetsu Shinkai, Shunichi Negoro, Fumio Imamura, Kenji Eguchi, Koji Takeda, Akira Inoue, Keisuke Tomii, Masao Harada, Noriyuki Masuda, Haiyi Jiang, Y. Itoh, Yukito Ichinose, Nagahiro Saijo, Masahiro Fukuoka